We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

108 hedge funds and large institutions have $95.6M invested in Praxis Precision Medicines in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

14% more funds holding

Funds holding: 95 → 108 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.15% less ownership

Funds ownership: 6.32% → 6.16% (-0.15%)

6% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 31

9% less capital invested

Capital invested by funds: $106M → $95.6M (-$9.9M)

Holders
108
Holders Change
+13
Holders Change %
+13.68%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
26
Increased
29
Reduced
31
Closed
13
Calls
$541K
Puts
–
Net Calls
+$541K
Net Calls Change
-$536K

Top Buyers

1
EC
EcoR1 Capital
California
+$4.27M
2
Millennium Management
Millennium Management
New York
+$2.34M
3
Goldman Sachs
Goldman Sachs
New York
+$1.75M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.66M
5
GCM
Graham Capital Management
Connecticut
+$1.38M

Top Sellers

1
State Street
State Street
Massachusetts
-$14M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$2.45M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.19M
4
LCM
Laurion Capital Management
New York
-$959K
5
Bank of America
Bank of America
North Carolina
-$925K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$645K +$622K +12,475 +193%
Morgan Stanley
27
Morgan Stanley
New York
$624K -$838K -16,823 -48%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$606K +$887K +17,803 New
AQR Capital Management
29
AQR Capital Management
Connecticut
$571K +$778K +15,623 +1,347%
Man Group
30
Man Group
United Kingdom
$544K +$795K +15,964 New
HF
31
HRT Financial
New York
$458K +$671K +13,460 New
LCM
32
Laurion Capital Management
New York
$450K -$959K -19,238 -59%
N
33
Nuveen
North Carolina
$446K -$148K -2,974 -18%
Squarepoint
34
Squarepoint
New York
$402K +$517K +10,377 +722%
XT
35
XTX Topco
Cayman Islands
$304K +$208K +4,180 +88%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$269K +$50K +1,003 +15%
CSS
37
Cubist Systematic Strategies
Connecticut
$267K -$8.02K -161 -2%
RJA
38
Raymond James & Associates
Florida
$267K – – –
UOC
39
UBS O'Connor
Illinois
$263K -$332K -6,667 -46%
BCM
40
Bridgeway Capital Management
Texas
$258K +$377K +7,573 New
SSA
41
Schonfeld Strategic Advisors
New York
$254K -$203K -4,065 -35%
OQS
42
Occudo Quantitative Strategies
Florida
$242K -$353K -7,089 -50%
Los Angeles Capital Management
43
Los Angeles Capital Management
California
$241K -$4.43K -89 -1%
Jane Street
44
Jane Street
New York
$235K +$21.5K +431 +7%
Point72 Asset Management
45
Point72 Asset Management
Connecticut
$227K – – –
SCM
46
Silverarc Capital Management
Massachusetts
$227K +$332K +6,667 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$195K – – –
Charles Schwab
48
Charles Schwab
California
$192K -$578K -11,609 -67%
Federated Hermes
49
Federated Hermes
Pennsylvania
$189K +$277K +5,565 New
TCM
50
Tekla Capital Management
Massachusetts
$170K – – –
1
2
3 4 5

PRAX Hedge Fund Activity: Q3 2022 in Review

108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2022, worth a combined $95.6M — down 9.4% from $106M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PRAX positions and 13 closed out — a net gain of 13 holders — while 29 added to existing stakes and 31 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $4.27M. The largest seller was State Street, cutting an estimated $14M.

  • 108 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2022, up from 95 in Q2 2022.
  • Funds reported $95.6M of Praxis Precision Medicines stock for Q3 2022, down 9.4% quarter-over-quarter.
  • 26 funds opened new Praxis Precision Medicines positions in Q3 2022 and 13 closed out, a net change of +13 holders.
  • The largest Praxis Precision Medicines buyer in Q3 2022 was EcoR1 Capital, an estimated $4.27M added.
  • The largest Praxis Precision Medicines seller in Q3 2022 was State Street, an estimated $14M sold.

Based on aggregated 13F filings for Q3 2022.